Safety of a novel gel formulation of clindamycin phosphate 1.2%-tretinoin 0.025%: Results from a 52-week open-label study

Cutis

Volumn 82, Issue 5, 2008, Pages 358-366

  Kircik, Leon H ^a,b,c   Peredo, Marina I ^c   Bucko, Alicia D ^d   Loss Jr , Robert W ^e   Fowler Jr , Joseph F ^f   Wortzman, Mitchell ^g   Neumaier, George J ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Physicians Skin Care PLLC   (United States)

^c Academic Dermatology Associates ^*  (United States)

^d Academic Dermatology Associates   (United States)

^e Dermatology Specialists PSC   (United States)

^f Medicis Pharmaceutical Corporation   (United States)

^g Medicis Pharmaceutical Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; CLINDAMYCIN PHOSPHATE - TRETINOIN FORMULATION; CLINDAMYCIN PHOSPHATE TRETINOIN FORMULATION; RETINOIC ACID; UNCLASSIFIED DRUG;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; FOLLOW UP; GEL; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; TIME; TREATMENT OUTCOME; UNITED STATES;

ACNE VULGARIS; ADOLESCENT; ADULT; CHILD; CLINDAMYCIN; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TRETINOIN; UNITED STATES; YOUNG ADULT;

EID: 58149383117     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(suppl 3):S200-S210.
2. Schlessinger J, Menter A, Gold M, et al; Ziana Study Group. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6:607-615.
3. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54:73-81.
4. Glass D, Boorman GC, Stables GI, et al. A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology. 1999;199:242-247.
5. Wolf JE Jr, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol. 2003;49(suppl 3):S211-S217.
6. Gollnick H, Cunliffe W, Berson D, et al; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1-S37.
7. Tanghetti EA. Combination therapy is the standard of care. Cutis. 2005;76(suppl 2):8-14.
8. Pariser DM, Westmoreland P, Morris A, et al. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6:899-905.
9. Mills OH Jr, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol. 1978;58:555-557.
10. Korting HC, Braun-Falco O. Efficacy and tolerability of combined topical treatment of acne vulgaris with tretinoin and erythromycin in general practice. Drugs Exp Clin Res. 1989;15:447-451.
11. Zouboulis CC, Derumeaux L, Decroix J, et al. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol. 2000;143:498-505.
12. Richter JR, Förström LR, Kiistala UO, et al. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol. 1998;11:227-233.
13. Data on file. Tedrow C, Lawson S. A multi-center, open-label, long-term, safety trial of Clin/RA gel in the treatment of acne vulgaris. Scottsdale, AZ: Medicis Pharmaceutical Corporation; 2006.
14. Plott RT. Unique aqueous gel formulation results in reduced risk of tretinoin-induced irritation bioassay. Poster presented at: 65th Annual Meeting of the American Academy of Dermatology; February 2-6, 2007; Washington DC. P132.
15. Ziana [package insert]. Scottsdale, AZ: Medicis, The Dermatology Company; 2006.